Biopharmaceutical development company CureVerse (CEO Seong-jin Cho) announced on the 9th that following the approval of the US FDA Phase 1 clinical trial IND (clinical trial plan), it has selected Mirae Asset Securities as the lead manager for its IPO (initial public offering) and will begin full-scale preparations with the goal of listing on KOSDAQ in 2027.
Curebus cited Mirae Asset Securities' experience in listing numerous bio companies as a key factor in selecting it as the lead manager, and announced that it plans to strategically respond to advanced screening criteria such as technological evaluation and listing review in the future.
Founded in 2021, Curebus is a company that develops new drugs based on small molecule compounds, and is characterized by possessing a library of new compounds designed in-house. Rather than existing commercialized compounds, it is building a pipeline centered on high-quality compounds that apply the 'Right Structure' concept.
The company's main pipeline, CV-01, was technology transferred to the Italian multinational pharmaceutical company Angelini Pharma in the preclinical stage in October 2023, and is currently undergoing phase 1 clinical trials at Seoul National University Hospital. The company plans to complete the clinical trial within this year.
CEO Cho Seong-jin said, “As the standards for technological evaluation are becoming more stringent, we will thoroughly prepare for systematic listing together with Mirae Asset Securities,” adding, “We will lay the foundation for sustainable growth and establish ourselves as an innovative bio company recognized both domestically and internationally.”
- See more related articles
You must be logged in to post a comment.